Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

As the EU patent expires on its flagship respiratory ... though the drug lags behind its rivals, Bayer/J&J's Xarelto and Pfizer/BMS's Eliquis, in market share terms. Meanwhile diabetes treatmeant ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

The researchers examined expected patient costs for preferred brand name drugs often lacking generic equivalents ... from $54.04 to $128.43 Xarelto (rivaroxaban) for blood clots, from $46.54 ...

However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...